Technical Insight

GAR INSIGHT
In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 — IVD Classification, Performance Evaluation, Conformity Assessment & CE Marking
GAR INSIGHT · IN VITRO DIAGNOSTICS & CE MARKING

In vitro diagnostic medical devices influence some of the most important healthcare decisions made for patients. A test result can contribute to diagnosis, screening, treatment selection, disease monitoring, prognosis or assessment of physiological and pathological conditions.

Regulation (EU) 2017/746, commonly known as the In Vitro Diagnostic Medical Devices Regulation or IVDR, establishes the European regulatory framework for in vitro diagnostic medical devices and replaced Directive 98/79/EC.

The IVDR introduced a fundamentally different risk-classification system based on Classes A, B, C and D. It also strengthened requirements for performance evaluation, clinical evidence, scientific validity, analytical performance, clinical performance, quality management, post-market surveillance and traceability.

For many IVD manufacturers, one of the most significant changes from the former Directive is the greatly increased requirement for Notified Body involvement. Under the IVDR, most Class B, C and D devices require independent conformity assessment.

This GAR Insight explains IVD qualification, classification, General Safety and Performance Requirements, performance evaluation, conformity assessment, Notified Body involvement, technical documentation, UDI, EUDAMED, post-market performance follow-up and CE marking.

ARTICLE GUIDE

Navigate This Article

Explore IVDR scope, Classes A–D, GSPR, performance evaluation, analytical and clinical performance, conformity assessment, technical documentation, UDI, EUDAMED and CE marking.

01
REGULATORY FOUNDATION

Understanding Regulation (EU) 2017/746

Regulation (EU) 2017/746 establishes requirements for in vitro diagnostic medical devices placed on the European Union market or put into service.

The Regulation repealed Directive 98/79/EC and introduced a substantially strengthened regulatory system based on risk classification, performance evidence and lifecycle oversight.

Legislation Regulation (EU) 2017/746
Common Name IVDR
Classification Classes A–D
CE Marking Required
The IVDR is a lifecycle regulatory framework. Manufacturers must establish conformity before market entry and continue monitoring safety and performance throughout the lifetime of the device.
↑ Back to Article Guide
02
QUALIFICATION

What Is an In Vitro Diagnostic Medical Device?

An IVD is generally a medical device intended by the manufacturer to be used in vitro for the examination of specimens derived from the human body, including blood and tissue donations, for the purpose of providing medically relevant information.

Reagents

Chemical or biological reagents used to detect, identify or measure an analyte or characteristic.

Calibrators & Controls

Products used to establish measurement relationships or verify assay performance.

Test Kits

Collections of components intended to perform a defined diagnostic examination.

Instruments

Analysers, readers and associated equipment intended for IVD use.

Specimen Receptacles

Devices specifically intended for the primary containment and preservation of specimens derived from the human body.

IVD Software

Software may itself qualify as an IVD when its intended purpose meets the applicable IVDR definition.

Not every laboratory product is an IVD. Qualification depends on intended purpose, specimen type, information produced and the manufacturer’s claims rather than merely the fact that a product is used in a laboratory.
↑ Back to Article Guide
03
INTENDED USE

Defining the Intended Purpose

Intended purpose is central to IVDR qualification, classification and performance evaluation. It should explain what the IVD measures or detects, the specimen used, the target population and the medical information the result is intended to provide.

Analyte or Marker

Identify the substance, organism, genetic marker or other characteristic being detected or measured.

Specimen

Define the intended specimen type, such as blood, serum, plasma, urine, tissue or another human-derived specimen.

Clinical Purpose

Explain whether the result contributes to diagnosis, screening, monitoring, prognosis, treatment selection or another purpose.

Intended User

Identify whether the device is intended for professional, laboratory, near-patient or self-testing use.

The intended purpose should remain consistent across the complete regulatory file. Labels, instructions, performance claims, classification, performance studies and marketing material should describe the same intended use.
↑ Back to Article Guide
04
RISK CLASSIFICATION

IVDR Classes A, B, C & D

Annex VIII of the IVDR contains seven classification rules used to determine whether an IVD falls into Class A, B, C or D.

Classification reflects the potential consequences of an incorrect test result for both the individual patient and public health.

Lower Risk

Class A

Generally lower-risk products such as certain instruments, specimen receptacles and general laboratory-related IVD products.

Moderate Risk

Class B

Devices not falling within the higher-risk rules and not qualifying as Class A are generally classified as Class B.

High Risk

Class C

Includes many devices where incorrect results could lead to serious consequences for patients or clinical management.

Highest Risk

Class D

Includes IVDs associated with particularly high public-health and individual risks, such as defined tests concerning transmissible agents.

IVD classification is rule-based. Manufacturers should review all potentially applicable Annex VIII rules and document why the selected rule produces the final classification.
↑ Back to Article Guide
05
ANNEX I

General Safety & Performance Requirements

IVDs must comply with the General Safety and Performance Requirements established in Annex I of the IVDR.

Risk Reduction

Risks should be reduced as far as possible without adversely affecting the benefit-risk ratio.

Performance

Devices should achieve the analytical and clinical performance claimed by the manufacturer.

Chemical & Biological

Materials, substances and biological characteristics should be appropriately assessed.

Infection & Contamination

Risks associated with contamination, specimens and biological materials should be controlled.

Electrical & Mechanical

Instruments and systems should address relevant electrical, mechanical, thermal and other physical hazards.

Information Supplied

Labels and instructions should communicate the intended use, performance characteristics, limitations and safety information.

The GSPR checklist should connect each requirement to evidence. Applicable requirements should be mapped to standards, risk controls, validation reports, performance evidence and other supporting documentation.
↑ Back to Article Guide
06
PERFORMANCE EVIDENCE

Performance Evaluation Under the IVDR

Performance evaluation is one of the defining components of IVDR conformity. It is a continuous process by which data are assessed and analysed to demonstrate the scientific validity, analytical performance and clinical performance of an IVD.

Scientific Validity

Establish the association between the analyte or marker and the relevant clinical or physiological condition.

Analytical Performance

Demonstrate the device’s ability to correctly detect or measure the intended analyte.

Clinical Performance

Demonstrate the device’s ability to yield results correlated with the relevant clinical condition or process.

Performance evaluation is not a single validation report. Scientific validity, analytical performance and clinical performance should form a connected evidence package supporting the intended purpose and claimed performance of the IVD.
↑ Back to Article Guide
07
ASSAY PERFORMANCE

Analytical Performance

Analytical performance demonstrates whether the IVD can reliably detect or measure the analyte under the conditions described by the manufacturer.

Analytical Sensitivity

Evaluate the device’s ability to detect low concentrations or relevant quantities of the target.

Analytical Specificity

Evaluate interference and cross-reactivity capable of affecting results.

Accuracy

Establish appropriate measures of trueness and precision where applicable.

Repeatability

Determine variation when measurements are repeated under the same conditions.

Reproducibility

Assess variation across relevant users, instruments, sites, lots or operating conditions.

Measuring Range

Establish applicable range, detection limits and quantitation characteristics where relevant.

Stability

Establish shelf life, in-use stability, transport stability and other relevant conditions.

Specimen Handling

Evaluate relevant specimen collection, storage, preparation and transport characteristics.

Cut-Off Values

Establish appropriate cut-off or decision limits where these influence interpretation of results.

Validation should represent the marketed test configuration. Reagent formulation, calibrators, instruments, software, specimen types and interpretation algorithms should correspond with the product described in the technical documentation.
↑ Back to Article Guide
08
CLINICAL EVIDENCE

Clinical Performance

Clinical performance concerns the ability of the IVD to produce results that correlate with a particular clinical condition, physiological or pathological process or state in accordance with its intended purpose.

Diagnostic Sensitivity

Evaluate the ability of the device to correctly identify subjects associated with the relevant condition where applicable.

Diagnostic Specificity

Evaluate the ability to correctly identify subjects not associated with the relevant condition where applicable.

Predictive Values

Positive and negative predictive values may be relevant depending on the test and intended clinical context.

Clinical Studies

Performance studies may be necessary where sufficient clinical performance evidence cannot otherwise be established.

Analytical performance and clinical performance answer different questions. A test can measure an analyte accurately while still lacking sufficient evidence that the result performs appropriately for the claimed clinical purpose.
↑ Back to Article Guide
09
TECHNICAL FILE

IVDR Technical Documentation

IVDR technical documentation should demonstrate that the device has been designed, manufactured and evaluated in accordance with the applicable requirements.

01
Device description. Identify the device, variants, accessories and intended purpose.
02
Qualification and classification. Document why the product is an IVD and the applicable Annex VIII rule.
03
Design and manufacturing information. Describe reagents, instruments, software, manufacturing processes and relevant sites.
04
GSPR evidence. Map applicable Annex I requirements to supporting conformity evidence.
05
Risk management. Maintain documented risk-management activities and controls.
06
Performance evaluation. Include scientific validity, analytical performance and clinical performance evidence.
07
Verification and validation. Maintain relevant assay, instrument, software, stability and other validation evidence.
08
Labels and instructions. Maintain controlled labelling and information supplied with the device.
09
Post-market documentation. Include applicable PMS and post-market performance follow-up documentation.
10
EU Declaration of Conformity. Maintain the completed declaration supporting CE marking.
The performance claims in the instructions should be traceable to the performance evidence. Sensitivity, specificity, measuring range, specimen claims, interference limitations and clinical-use claims should correspond with the validated device.
↑ Back to Article Guide
10
QUALITY SYSTEM

Quality Management Under the IVDR

Manufacturers must establish and maintain a quality management system appropriate to the device, risk class and regulatory responsibilities.

Design Controls

Development of assays, instruments and software should be planned, reviewed, verified and validated.

Supplier Controls

Critical raw materials, reagents, components and outsourced processes should be appropriately controlled.

Production Controls

Manufacturing processes should consistently produce devices meeting approved specifications.

Lot Control

Reagent and test-kit production can require appropriate lot qualification and release controls.

CAPA

Quality issues and nonconformities should feed into corrective and preventive action processes.

Post-Market Feedback

Complaints, vigilance and performance data should feed back into quality and risk-management processes.

ISO 13485 can support the quality system, but the legal obligations come from the IVDR. The manufacturer’s QMS should be assessed against the actual requirements of Regulation (EU) 2017/746 and the particular IVD conformity route.
↑ Back to Article Guide
11
MARKET ACCESS ROUTE

IVDR Conformity Assessment by Device Class

Device classification determines the level of conformity assessment and degree of third-party involvement required.

IVD Class General Conformity Position Notified Body
Class A — non-sterile Manufacturer can generally complete conformity assessment without Notified Body involvement. Generally no
Class A — sterile Notified Body involvement applies to the aspects concerned with establishing, securing and maintaining sterile conditions. Yes — limited scope
Class B Requires conformity assessment involving an appropriately designated Notified Body. Yes
Class C Requires Notified Body conformity assessment and more extensive technical and performance evidence appropriate to the risk. Yes
Class D Subject to the highest level of IVDR conformity assessment, including additional requirements applicable to highest-risk devices. Yes
The IVDR moved many IVDs from self-declaration to third-party assessment. Manufacturers should establish classification and Notified Body requirements early because conformity assessment capacity and technical-documentation readiness can significantly affect the market-access timeline.
↑ Back to Article Guide
12
INDEPENDENT ASSESSMENT

The Role of the Notified Body

Notified Bodies designated under the IVDR assess conformity for devices requiring independent third-party involvement.

QMS Assessment

The manufacturer’s quality management system can be audited against the applicable IVDR conformity requirements.

Technical Documentation

Device documentation and performance evidence are reviewed according to the applicable conformity assessment route.

Performance Evidence

Scientific validity, analytical performance and clinical performance evidence may form part of the assessment.

Surveillance

Continuing surveillance is performed where required to maintain certification.

Notified Body designation must cover the relevant IVD scope. Manufacturers should verify the organisation’s IVDR designation and applicable device codes before assuming it can assess the device.
↑ Back to Article Guide
13
TRACEABILITY & MARKET ACCESS

UDI, EUDAMED, Declaration & CE Marking

IVDR market access includes device identification, registration, economic-operator requirements, the EU Declaration of Conformity and CE marking.

UDI

Unique Device Identification supports traceability of IVDs throughout the supply chain and device lifecycle.

Basic UDI-DI

The Basic UDI-DI provides a regulatory identifier for a device family and is used within key regulatory documentation.

EUDAMED

Applicable actor, device and certificate information is managed through the European Database on Medical Devices.

EU Declaration

The manufacturer draws up the EU Declaration of Conformity after applicable conformity requirements have been satisfied.

CE Marking

CE marking is applied after the applicable conformity assessment procedure has been satisfactorily completed.

Authorised Representative

Manufacturers established outside the Union require an EU authorised representative in accordance with the IVDR.

EUDAMED obligations are now operationally important. As of 28 May 2026, the first four EUDAMED modules are mandatory to use, including Actor Registration, UDI/Device Registration, Notified Bodies & Certificates and Market Surveillance.
↑ Back to Article Guide
14
AFTER MARKET ENTRY

Post-Market Surveillance & Performance Follow-Up

IVDR compliance continues after the device is placed on the market. Manufacturers must actively collect and evaluate information about device quality, safety and performance.

Post-Market Surveillance

PMS should systematically gather and analyse information from marketed devices.

PMPF

Post-Market Performance Follow-Up supports continuous evaluation of scientific validity, analytical performance and clinical performance.

Vigilance

Serious incidents and field safety corrective actions must be handled according to applicable IVDR requirements.

Performance Updates

New performance data can require updates to the performance evaluation and technical documentation.

Risk Updates

Post-market information should feed back into the risk-management process.

CAPA

Quality and performance problems should trigger appropriate investigation and corrective action.

Performance evaluation does not end at CE marking. Post-market information should continuously confirm—or challenge—the assumptions concerning scientific validity, analytical performance, clinical performance and risk on which conformity was established.
↑ Back to Article Guide

From IVD Development to Demonstrable European Conformity

Successful IVDR compliance begins with a clearly defined intended purpose and defensible classification. Those decisions determine the performance evidence, conformity assessment route and level of independent regulatory scrutiny that follow.

Manufacturers should then build a connected evidence system linking risk management, General Safety and Performance Requirements, scientific validity, analytical performance, clinical performance, verification, quality management and technical documentation.

For most Class B, C and D devices, this evidence must support conformity assessment by an appropriately designated Notified Body before CE marking.

The responsibility continues after market entry through post-market surveillance, vigilance and post-market performance follow-up.

The Performance Question

Does the available scientific, analytical and clinical evidence demonstrate that the IVD reliably performs for its stated intended purpose and patient or population context?

The Conformity Question

Can the manufacturer demonstrate through classification, performance evaluation, risk management, technical documentation, quality controls and post-market processes that the IVD continues to satisfy Regulation (EU) 2017/746?

The defining IVDR compliance question is: can the manufacturer demonstrate that the IVD actually placed on the European market corresponds with the intended purpose, classification, scientific validity, analytical performance, clinical performance, technical documentation and quality system on which its CE marking is based?
Technical note: Regulation (EU) 2017/746 governs in vitro diagnostic medical devices within its scope and establishes risk Classes A, B, C and D. Product-specific requirements depend on qualification, intended purpose, classification, GSPR applicability, performance evaluation, device characteristics and conformity assessment route. Most Class B, C and D devices require Notified Body involvement, while non-sterile Class A devices can generally follow manufacturer self-assessment. Manufacturers should verify the current consolidated Regulation, applicable transitional provisions, MDCG guidance, Common Specifications, harmonised standards and current EUDAMED obligations when conducting a device-specific regulatory assessment. This article provides general technical information and does not replace an IVD-specific regulatory, performance or conformity assessment.
GLOBAL ALLIANCE REGISTER

How Global Alliance Register Can Support You

Global Alliance Register supports manufacturers, suppliers and responsible economic operators with independent technical-assurance services relevant to EU In Vitro Diagnostic Regulation (IVDR) within the healthcare and medical technology context. Based on the article's emphasis on conformity assessment, regulatory review and performance and reliability verification, GAR can coordinate competent specialists, laboratories, inspectors, auditors and accredited conformity-assessment resources as appropriate to the actual technical need. Within the context of this article, Global Alliance Register can support you in the following areas:

01

Determine the applicable conformity-assessment route for EU In Vitro Diagnostic Regulation (IVDR), coordinate the required technical evidence and support independent third-party or Notified Body involvement where the governing framework requires it.

02

Review test records, inspection evidence, calculations, reports and other technical documentation relating to EU In Vitro Diagnostic Regulation (IVDR) for completeness, consistency and traceability.

03

Review the applicable regulatory, technical and scope requirements for EU In Vitro Diagnostic Regulation (IVDR) and define the responsibilities, classifications and assurance pathway relevant to the product or equipment.

04

Map the applicable standards, specifications, acceptance criteria and technical requirements for EU In Vitro Diagnostic Regulation (IVDR) to the evidence needed to demonstrate compliance, quality or performance.

05

Review commissioning readiness and coordinate functional, performance and acceptance verification relevant to EU In Vitro Diagnostic Regulation (IVDR), including defects, retesting and close-out evidence.

Scroll to Top